BioStem Technologies expands wound care portfolio with USD40M BioTissue acquisition

USA—BioStem Technologies has taken a significant step to strengthen its position in the wound care market by acquiring BioTissue Holdings’ surgical and wound care business unit in a transaction valued at up to USD40 million.

The acquisition marks a strategic expansion of BioStem’s existing product portfolio and establishes the company’s presence in hospital-based wound treatment applications.

Under the terms of the agreement, BioStem will pay USD 15 million upfront in cash to acquire the Florida-based business unit.

The deal structure includes additional performance-based payments that could bring the total transaction value to USD 40 million.

BioTissue stands to receive up to USD10 million if the acquired unit achieves clearance from the US Food and Drug Administration (FDA) for a pipeline product currently in development.

Furthermore, the deal includes the potential for an additional USD 15 million tied to reaching specified commercial milestones.

The acquisition adds two key products to BioStem’s portfolio: Neox and Clarix, both cryopreserved amniotic membrane allografts.

These products complement BioStem’s current offerings, which include dehydrated amniotic-derived allografts such as AmnioWrap, a product designed to treat chronic and acute wounds.

The newly acquired assets will enable BioStem to expand its reach across multiple healthcare settings, including hospital inpatient units, outpatient facilities, and ambulatory surgery centers.

Neox and Clarix serve distinct but related purposes in the medical field. Neox addresses both chronic and acute wound applications, providing healthcare professionals with treatment options for difficult-to-heal wounds.

Clarix, on the other hand, targets surgical applications with specific uses in procedures such as tendon repair and nerve protection.

Both products utilize tissue derived from human amniotic and umbilical cord sources, which are obtained from consenting donors through ethical procurement processes.

BioTissue’s proprietary CryoTek preservation technology represents a critical component of the acquisition.

This technology employs cryopreservation methods specifically designed to maintain the structural integrity of the allograft’s extracellular matrix and preserve its bioactive factors.

These elements play essential roles in supporting the body’s natural healing processes and contribute to the effectiveness of the wound care products.

Jason Matuszewski, CEO of BioStem Technologies, emphasized the strategic importance of the acquisition for the company’s growth trajectory.

He noted that the deal provides BioStem with an immediate entry point into hospital-based applications, an area where the company previously had limited presence.

The transaction also diversifies BioStem’s technological capabilities by adding a new platform for preserving placental and umbilical tissue allografts.

Matuszewski further explained that the acquired technology creates opportunities for BioStem to enter valuable adjacent market segments.

These include applications for acute surgical wounds, burn treatment, and soft-tissue repair procedures.

The CEO highlighted that the acquisition creates synergies across the company’s entire product range while simultaneously diversifying revenue sources and reducing dependence on any single product line.

The wound care sector continues to experience robust growth, driven by an aging global population, rising prevalence of chronic conditions such as diabetes, and increasing awareness of advanced wound treatment options.

According to market analysis from GlobalData, the wound care industry is expanding at a compound annual growth rate of 4.8 percent.

The sector’s valuation is projected to climb from USD33.19 billion in 2024 to more than USD53 billion by 2034.

Recent consolidation activity demonstrates the sector’s attractiveness to major healthcare companies.

In November 2025, Solventum completed its acquisition of Acera Surgical, a Missouri-based company, in a deal valued at up to USD 850 million.

That transaction gave Solventum access to the Restrata line of electrospun fiber matrices used in wound treatment.

The Solventum-Acera deal represents the largest wound care acquisition since Coloplast purchased Kerecis, an Icelandic developer of wound care technology based on intact fish skin, for USD1.3 billion in 2023.